Skip to main content
x

Recent articles

No SOS for Bayer's SOS1

The group goes after a KRAS-related target on which Boehringer recently gave up.

Clouds loom for Novartis’s MorphoSys buy

Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.

Triple meeting 2024 – Revolution shows selective KRAS promise

RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.

Triple meeting 2024 – Aktis radiotherapy heads for the clinic

AKY-1189 could be used in Padcev-relapsed patients, and in cancers beyond bladder.

Triple meeting 2024 – Tyra’s targeted FGFR3 push

The company reckons it’s got what it takes to hit the right member of the FGFR family.

Triple meeting 2024 – casdatifan looks like Welireg

There’s little to distinguish the two HIF2α inhibitors in kidney cancer.